Advancing Metabolic
Continuum Research

Metabolic Continuum

We are the leading clinical research organization focused on metabolic continuum diseases. We collaborate globally with pharmaceutical, biotech, and medical device partners to advance clinical research for new therapeutics and improve health outcomes for patients. This is based on a deep understanding of the pathophysiology and interconnectedness of disorders across the continuum of metabolic diseases.

Metabolic Continuum video thumbnail
Doctor reviewing patient information with patient

Recognizing metabolic diseases as a continuum represents a shift from traditional silos of disease-specific research. We enable a clearer understanding of complex concomitant disorders that share common risk factors, including obesity, diabetes, steatotic liver disease, cardiovascular disease, chronic kidney disease, and neurodegenerative diseases.

Hex diagram of hexes showing lifeforms in metabolic research

For over 20 years, ProSciento has been at the forefront of supporting clinical research for the continuum of metabolic diseases, offering unparalleled experience in obesity, diabetes, and steatotic liver disease to pharmaceutical, biotech, and medical device companies globally. Our science-driven expertise guides the development of new clinical endpoints and drug classes for targeted therapies, advancing precision medicine to improve patient care and therapeutics.

Partnering with Prosciento

ProSciento’s science-driven approach provides clients seamless support from early development strategy to decision milestones.

Collaborating with us ensures interactions with a team of experts, focused on tailoring services to suit your individualized metabolic continuum program needs.

chat bubble icon Speak with an expert

ProSciento team members